0001104659-16-127402.txt : 20160615 0001104659-16-127402.hdr.sgml : 20160615 20160615172039 ACCESSION NUMBER: 0001104659-16-127402 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160609 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20160615 DATE AS OF CHANGE: 20160615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENOMIC HEALTH INC CENTRAL INDEX KEY: 0001131324 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770552594 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51541 FILM NUMBER: 161716016 BUSINESS ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-556-9300 MAIL ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 8-K 1 a16-13355_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  June 9, 2016

 

GENOMIC HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware
(State or Other Jurisdiction of
Incorporation)

 

000-51541
(Commission File Number)

 

77-0552594
(I.R.S. Employer
Identification No.)

 

301 Penobscot Drive

 

 

Redwood City, CA

 

94063

(Address of principal executive offices)

 

(Zip Code)

 

(650) 556-9300

(Registrant’s telephone number,
including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

 

 

 


 

Item 5.07                                           Submission of Matters to a Vote of Security Holders.

 

The following actions were taken at the Annual Meeting of Stockholders of Genomic Health, Inc. (the “Company”), held on June 9, 2016:

 

1.                                      The following Directors were elected to serve until the 2017 Annual Meeting or until their successors are duly elected and qualified:

 

 

 

For

 

Withheld

 

Broker
Non-Votes

 

 

 

 

 

 

 

 

 

Kimberly J. Popovits

 

26,018,045

 

778,521

 

4,379,970

 

 

 

 

 

 

 

 

 

Felix J. Baker, Ph.D.

 

24,416,319

 

2,380,247

 

4,379,970

 

 

 

 

 

 

 

 

 

Julian C. Baker

 

25,556,100

 

1,240,466

 

4,379,970

 

 

 

 

 

 

 

 

 

Fred E. Cohen, M.D., D.Phil.

 

19,702,606

 

7,093,960

 

4,379,970

 

 

 

 

 

 

 

 

 

Henry J. Fuchs, M.D.

 

24,577,808

 

2,218,758

 

4,379,970

 

 

 

 

 

 

 

 

 

Ginger L. Graham

 

26,225,160

 

571,406

 

4,379,970

 

 

 

 

 

 

 

 

 

Randall S. Livingston

 

26,710,420

 

86,146

 

4,379,970

 

 

2.                                      An Amendment to the Amended and Restated Genomic Health, Inc. 2005 Stock Incentive Plan was approved.

 

For

 

Against

 

Abstain

 

Broker
Non-Votes

 

17,643,765

 

9,135,413

 

17,388

 

4,379,970

 

 

3.                                      The compensation of the Company’s named executive officers was approved, on a non-binding advisory basis.

 

For

 

Against

 

Abstain

 

Broker
Non-Votes

 

25,339,534

 

1,435,535

 

21,497

 

4,379,970

 

 

4.                                      The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2016 fiscal year was approved.

 

For

 

Against

 

Abstain

 

 

 

31,040,845

 

96,785

 

38,906

 

 

 

 

5.                                      The stockholder proposal concerning proxy access was not approved.

 

For

 

Against

 

Abstain

 

Broker
Non-Votes

 

9,409,365

 

17,096,128

 

291,073

 

4,379,970

 

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 15, 2016

 

 

GENOMIC HEALTH, INC.

 

 

 

 

 

By:

/s/ G. Bradley Cole

 

 

 

G. Bradley Cole

 

 

 

Chief Financial Officer

 

 

3